Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 6
Opinion
Video
Evolving Best Practices for ESR1 Testing
The breast cancer experts share their clinical experiences and strategies regarding the optimal timing for testing ESR1 mutations in patients with HR+/HER2- metastatic breast cancer, elaborating on how the specific points in the treatment journey at which they recommend testing influence their subsequent treatment decisions and overall approach to patient management.
EP: 1.Prevalence and Testing Strategies for ESR1
EP: 2.Evolution of Testing Strategies for ESR1
EP: 3.Dynamics of ESR1 Alterations and Serial Liquid Biopsies
EP: 4.Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
EP: 5.EMERALD Study Design and Results for Elacestrant
Now Viewing
EP: 6.Evolving Best Practices for ESR1 Testing
EP: 7.Case Presentation 2: Co-mutations in ESR1 and PIK3CA
EP: 8.PIK3CA Mutations and Delivering PI3K Inhibitors
EP: 9.PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors
EP: 10.Combinations and Treatment Sequence Strategies in Breast Cancer
EP: 11.Future Directions and Unmet Needs in HR+ Breast Cancer
EP: 12.Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer
- In your clinical practice, at what specific points in the treatment journey would you recommend testing for ESR1 mutations, and how does the timing of testing impact your subsequent treatment decisions and approach?
- What are your institution’s protocols and best practices regarding the timing and frequency of ESR1 mutations testing throughout the treatment journey
- Can you elaborate further on what an ESR1 mutation is?
- What are your institution’s protocols and best practices regarding the timing and frequency of ESR1 mutations testing throughout the treatment journey
Related Videos
Related Content
